Augmentation strategies in geriatric depression

International Journal of Geriatric Psychiatry

Volumn 10, Issue 2, 1995, Pages 137-146

  Flint, Alastair J ^a  

^a TORONTO REHABILITATION INSTITUTE   (Canada)

Author keywords

aged; augmentation; Depressive disorder; geriatric psychiatry; refractory; treatment resistant

Indexed keywords

ANTIDEPRESSANT AGENT; BUSPIRONE; CARBAMAZEPINE; CENTRAL STIMULANT AGENT; CLOMIPRAMINE; CLONAZEPAM; DESIPRAMINE; DOXEPIN; LIOTHYRONINE; LITHIUM; MIANSERIN; MONOAMINE OXIDASE INHIBITOR; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TRANYLCYPROMINE; VALPROIC ACID;

ADULT; AGED; ATAXIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELIRIUM; DEMENTIA; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERANCE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; REVIEW; SIDE EFFECT; TACHYCARDIA; TREATMENT FAILURE;

EID: 0028933399     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.930100209     Document Type: Article

References (77)

1. Elderly depressed females as a possible subgroup of patients responsive to methylphenidate.
2. Toxicity resulting from lithium augmentation of antidepressant treatment in elderly patients.
3. Fluoxetine potentiation by buspirone: Three case histories.
4. Adverse reactions to antiepileptic drugs: A multicenter survey of clinical practice.
5. Concomitant imipramine and methylphenidate administration: A case report.
6. Sodium valproate augmentation of fluoxetine or fluvoxamine effects.
7. Lithium addition in tricyclic‐resistant unipolar depression: A placebo‐controlled study
8. Thyroid hormone supplementation of fluoxetine treatment.
9. Carbamazepine for treatment‐resistant melancholia.
10. A comparison of electroconvulsive therapy and combined phenelzine–amitriptyline in refractory depression.
11. Carbamazepine addition in tricyclic antidepressant‐resistant unipolar depression.
12. Combined MAOI, TCA, and direct stimulant therapy of treatment‐resistant depression.
13. The combination of lithium carbonate and an MAOI in refractory depressions.
14. Lithium augmentation in the treatment of refractory depression in old age.
15. The optimum duration of antidepressant treatment in the elderly.
16. A prospective study of lithium augmentation in antidepressant‐resistant geriatric depression.
17. Lithium carbonate augmentation of desipramine and fluoxetine in refractory depression.
18. Use of lithium in elderly psychiatric patients: A review of the literature.
19. Lithium potentiation of tricyclic antidepressants following lack of T3 potentiation.
20. Comparative efficacy and safety of MAOIs versus TCAs in treating depression in the elderly.
21. Failure of T3 to potentiate tricyclic antidepressant response.
22. Treatment‐resistant depression in the elderly.
23. Potentiation of antidepressant effects by L‐triiodothyronine tricyclic non‐responders.
24. Augmenting fluoxetine with dextroamphetamine to treat refractory depression.
25. The clinical meaning of refractory depression: A review for the clinician.
26. A rating scale for depression.
27. Lithium carbonate augmentation of antidepressant treatment: An effective prescription for treatment‐refractory depression.
28. Possible augmentation of antidepressant response by buspirone.
29. T3 and lithium potentiation of tricyclic antidepressants.
30. Triiodothyronine potentiation of fluoxetine in depressed patients.
31. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression.
32. A comparison of triiodothyronine and thyroxine in the potentiation of tricyclic antidepressants.
33. A placebo‐controlled comparison of lithium and triiodothyronine augmentation of tricyclic an tidepressants in unipolar refractory depression.
34. Predictors of response to lithium and triiodothyronine augmentation of anti depressants in tricyclic non‐responders.
35. The benefit of lithium carbonate adjunct in refractory depression: Fact or faction?
36. Lithium augmentation in refractory depression.
37. Lithium augmentation for refractory depression in old age
38. Treatment of depression with clonazepam.
39. Use of antidepressants in medically ill older patients.
40. Lithium–antidepressant combinations in the treatment of depressed, physically ill geriatric patients.
41. Lithium augmentation for treatment‐resistant depression in the elderly.
42. Combined drug therapy for an elderly depressed patient.
43. Treatment of a refractory depression with a combination of fluoxetine and d‐amphetamine.
44. Valproate in the treatment of bipolar disorder: Literature review and clinical guidelines.
45. Aging and extrapyramidal function.
46. The influence of age on lithium efficacy and side‐effects in out‐patients.
47. Augmentation regimens for depression.
48. Methodological considerations for the study of treatment‐resistant depression
49. Lithium drug interactions altering the intracellular lithium level: An in vitro study.
50. Combined MAOI‐TCA treatment in refractory depression
51. Mechanism of action of carbamazepine and related anticonvulsants in affective illness
52. Serious adverse effects of combining fluoxetine and tricyclic antidepressants.
53. Somatic therapy for major depressive disorder: Selection of an antidepressant.
54. Lithium augmentation of combined neuroleptic‐tricyclic treatment in delusional depression.
55. The safety and efficacy of combined amitriptyline and tranylcypromine antidepressant treatment.
56. Use of psychostimulants for the elderly.
57. Lithium treatment in older patients.
58. Fluoxetine enhancement of heterocyclic antidepressants
59. Stimulants in the treatment of depression: A critical overview.
60. Treatment of depression resistant to tricyclic antidepressants, related drugs or MAO‐inhibitors by lithium addition: Review of the literature.
61. Treatment of endogenous depressions resistant to tricyclic antidepressants or related durgs by lithium addition: Results of a placebo‐controlled double‐blind study.
62. Combination treatment with noradrenaline and serotonin reuptake inhibitors in resistant depression.
63. Diurnal variation in methylphenidate stimulant response in major depression.
64. Adverse effects of lithium therapy in the acutely ill elderly patient.
65. Lithium augmentation therapy in tricyclic‐resistant depression: A controlled trial using lithium in low and normal doses.
66. Diurnal variation in methylphenidate stimulant response in major depression.
67. Lithium augmentation in geriatric depression.
68. Cognitive dysfunction associated with antiepileptic drug therapy.
69. Fluoxetine added to non‐MAOI antidepressants converts nonresponders to responders: A preliminary report.
70. Tricyclic augmentation of fluoxetine.
71. A potential clinical use for methylphenidate with tricyclic antidepressants.
72. Combined monoamine oxidase inhibitor–tricyclic antidepressant treatment: A pilot study.
73. Lithium–tetracyclic antidepressant combination therapy for presenile depressed patients.
74. Controlled trial of trimipramine, monoamine oxidase inhibitors, and combined treatment in depressed out‐patients.
75. Adjunctive lithium carbonate in nortriptyline‐resistant elderly depressed patients.
76. Adjunct low dose lithium carbonate in treatment‐resistant depression: A placebo‐controlled study.